← All trials
NCT05737615
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 10, 2023
- Primary completion
- Feb 10, 2025
- Completion date
- Feb 10, 2025
- First posted
- Feb 21, 2023
- Last posted
- Aug 23, 2023
- Enrollment
- 22
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Memorial Sloan-Kettering Cancer CenterLead sponsor
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.